Metabolite patterns in blood and urine of people with fibrosing interstitial lung disease and precapillary pulmonary hypertension
Official title: Blood and uRine Metabolomics Exploration for Assessing Thoracic Health After Treatment of Group 3 Pulmonary Hypertension
Run by Hospices Civils de Lyon · NCT07254338 · Data updated 2026-11-12
We will see if blood and urine metabolite patterns change in people with fibrosing interstitial lung disease who have precapillary pulmonary hypertension, before and during treatments such as inhaled treprostinil.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron, Rhone) |
| Status | Recruiting |
| Started | February 16, 2026 |
| Main results expected | August 16, 2029 |
| Study ends | August 16, 2029 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07254338 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with progressive fibrosing interstitial lung disease who are suspected of having precapillary pulmonary hypertension, are scheduled for hemodynamic confirmation, and can give informed consent for blood and urine sampling.
✕Probably not a fit
Patients with other forms of pulmonary hypertension (for example PAH or CTEPH), those not undergoing catheterization, or those unwilling/unable to provide samples are unlikely to gain direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project collects blood and urine samples from patients with fibrosing interstitial lung disease suspected of having precapillary pulmonary hypertension. Samples are obtained around diagnostic right heart catheterization and during follow-up, including before and after initiation of pulmonary hypertension therapies such as inhaled treprostinil. Metabolomic profiling will compare systemic metabolite patterns with hemodynamic findings and treatment exposure to identify biochemical signatures linked to disease state and treatment response. The protocol is minimally invasive and does not alter standard clinical care.
Why it matters
Potential benefit: If successful, the work could identify metabolic markers that help predict who benefits from PH treatments or guide more personalized therapy for ILD-related PH.
How similar studies have gone: While inhaled treprostinil has shown clinical benefit in recent trials for ILD‑PH, using metabolomics to track systemic treatment effects in this population is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering from progressive interstitial lung disease (ILD) and especially lung fibrosis * Suspicion of precapillar pulmonary hypertension (group 3 PH / ILD-PH) * Patients undergoing cardiac catheterisation for haemodynamic confirmation * Patient who has given informed consent Exclusion Criteria: * Patients suffering from other forms of PH (i.e. PAH, CTEPH, heart failure, multifactorial
Where it's running
-
Hôpital Cardiologique et Pneumologique Louis Pradel
Bron, Rhone, France Recruiting
Study contacts
- Study coordinator: Ségolène TURQUIER
- Email: segolene.turquier@chu-lyon.fr
- Phone: 04 72 35 73 32
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Treatment Response in Myositis-Associated RP-ILD in Adults
This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.